


 Cite this: *RSC Adv.*, 2025, 15, 19158

# Theoretical insight and molecular recognition of fluconazole molecularly imprinted polymers: a combined computational and experimental analysis†

 Untung Gunawan,<sup>a</sup> Slamet Ibrahim,<sup>b</sup> Atthar Luqman Ivansyah<sup>cd</sup> and Sophi Damayanti<sup>ef</sup>

Insufficient surveillance and diagnosis result in a minimum of 150 million cases of serious fungal infections reported annually. The WHO has compiled a list of priority pathogens to encourage research and investment in fungal infections and antifungal resistance in late 2022. Among these, *Candida albicans* is classified as a critical pathogen. Fluconazole is widely recognized as an effective medication for the treatment and prevention of both mucosal and invasive candidiasis. Molecularly imprinted polymer (MIP) could enhance separation selectivity in fluconazole bioanalysis. The objective of this research is to develop an MIP for fluconazole by analyzing interactions identified in prior research and incorporating established improvements for MIP synthesis that cannot be observed through laboratory experimentation. Based on binding affinity, intermolecular hydrogen bonds, complexation energy, and thermodynamic characteristics, 2-acrylamido-1-ethanesulfonic acid was chosen as the optimal monomer. The HOMO–LUMO investigation revealed the localization of the orbitals from the guest to the host. The FMO study indicated that chloroform was the most suitable solvent for complex formation. The QAIM, NBO, and NCI-RDG analyses identified the hydrogen bond formed between the H51 atom of the monomer and the N33 atom of fluconazole, determined to be the most significant hydrogen bond in the host–guest interaction. The interaction energy from multi-monomer interaction showed that a 1 : 6 ratio is the best ratio in forming a pre-polymerization complex between the template and monomer. Based on the findings of this study, it is anticipated that the computational analysis may be utilized for rational design for the enhancement of prior studies and future laboratory investigations.

Received 7th May 2025

Accepted 29th May 2025

DOI: 10.1039/d5ra03211c

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## 1 Introduction

Insufficient surveillance and diagnostic invasive fungal infections cause at least 150 million severe fungal infections and a total of 1.5 million deaths annually. Existing reports show the annual incidence rates for aspergillosis, candidiasis, and

invasive mucormycosis are estimated to exceed 300 000, 750 000, and 10 000 cases, respectively.<sup>1–3</sup> The epidemiology of invasive fungal infections causes a mortality rate of 30–70% in invasive aspergillosis, 40% in invasive candidiasis, and 35–100% in invasive mucormycosis.<sup>4</sup> The use of antifungal drugs only demonstrates partial success in improving the prognosis of infected patients, and this is compounded by the rapid evolution of drug resistance among fungal species.<sup>5</sup> Due to an increase in critically ill and immunocompromised patients, as well as an increase in fungal infections, there have been changes in the evolution, prognosis, diagnosis, and treatment of fungal diseases lately.<sup>6</sup> In late 2022, the World Health Organisation (WHO) published a list of fungal priority pathogens (FPPL) to promote worldwide research in fungal illnesses and antifungal resistance. Three priority groups classify the nineteen species linked to invasive fungal diseases: critical, high, and medium. Four pathogens, *Candida auris*, *Cryptococcus neoformans*, *Aspergillus fumigatus*, and *Candida albicans*, are considered to be critical fungi.<sup>7</sup> *C. albicans*, a pathogenic fungus, has the ability to invade healthy humans and induce

<sup>a</sup>Department of Pharmacy, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, 14440, Indonesia. E-mail: [untung.gunawan@atmajaya.ac.id](mailto:untung.gunawan@atmajaya.ac.id)

<sup>b</sup>Faculty of Pharmacy, Universitas Jenderal Achmad Yani, Cimahi, 40531, Indonesia

<sup>c</sup>Instrumentation and Computational Physics Research Group, Department of Physics, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, 40132, Indonesia

<sup>d</sup>Master Program in Computational Science, Faculty of Mathematics and Natural Science, Institut Teknologi Bandung, 40132, Indonesia

<sup>e</sup>Department of Pharmacochemistry, School of Pharmacy, Institut Teknologi Bandung, 40132, Indonesia

<sup>f</sup>University Center of Excellence on Artificial Intelligence for Vision, Natural Language Processing & Big Data Analytics (U-CoE AI-VLB), Institut Teknologi Bandung, 40132, Indonesia

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d5ra03211c>



invasive candidiasis or infections of the mucosae. Invasive candidiasis is a severe and sometimes fatal illness characterized by a high death rate. However, the treatment for candidiasis is feasible, and the occurrence of antifungal resistance is generally unusual.<sup>8</sup> The Infectious Diseases Society of America (IDSA) recommends using echinocandins, triazole antifungals, flucytosine, and amphotericin B as treatment options for invasive candidiasis.<sup>9</sup> The initial treatment of choice for *C. albicans* is echinocandin, whereas fluconazole is an alternative option for initial treatment. Additionally, fluconazole is employed as a step-down therapy. Although included in the essential medicines list (EML) in 2021, echinocandins remain inaccessible in many countries. Consequently, fluconazole continues to be the preferred choice in these countries.<sup>10,11</sup>

Several techniques have been established for the analysis of fluconazole bioanalysis. Each biological matrix possesses advantages and disadvantages, and the data's clinical interpretation relies highly on the matrix.<sup>12,13</sup> Optimizing the sample preparation in biological matrices will improve the recoveries and minimize any interferences, such as endogenous compounds, during the analysis.<sup>14</sup> The current techniques employed for the separation of triazole antifungals in biological samples encompass liquid–liquid extraction (LLE), protein precipitation, and solid-phase extraction (SPE).<sup>15</sup> The utilization of molecularly imprinted polymer (MIP) has emerged as a separation technique aimed at enhancing the selectivity of analyte separation. MIP refers to artificially synthesized receptors designed to bind to a specific substance selectively. Therefore, they can be considered analogous to the natural antibody–antigen systems.<sup>16</sup> Compared to other separation methods, MIP offers several advantages, such as the ability to specifically recognize analyte molecules and a wide range of applications in different fields. As a result, MIPs are useful for various purposes, including sorbents for solid phase extraction and stationary phases in column chromatography.<sup>17,18</sup> The widespread use of MIP as a novel approach for preparation methods shows its effectiveness in analyzing compounds in complex matrices while simultaneously requiring relatively small sample quantities.<sup>19,20</sup>

Nowadays, the utilization of computational methods in this design provides the production of high-affinity polymers through a systematic approach, resulting in significant time and resource savings.<sup>21</sup> The use of computational design for MIP is anticipated to become a standard practice in the pre-synthesis stage, enabling the creation of polymers that exhibit enhanced affinity and selectivity towards specific target molecules.<sup>22</sup> The computational methodology commonly utilized for the synthesis of MIP involves the application of molecular modeling techniques, such as quantum mechanics (QM), molecular mechanics (MM), or molecular dynamics (MD). The computational expense associated with MM optimization is significantly lower than QM, resulting in a much higher computational speed, which is much faster than QM.<sup>23</sup> Nevertheless, this approach lacks to compensate for electron interactions and is incapable of accurately simulating that in chemical reactions, thereby diminishing the accuracy of the calculation.<sup>24</sup>

Previous studies have demonstrated the application of multi-template MIP for the investigation of triazole antifungals, including voriconazole, itraconazole, and fluconazole. The multi-template MIP facilitates the simultaneous extraction of analytes, which minimizes the effort needed to prepare different MIPs for each analyte individually. However, MIPs utilizing multiple template molecules exhibit several drawbacks that require consideration, such as competition in the MIP's ability to recognize template molecules, which causes lower selectivity and adsorption capacity compared to single templates due to the reduction in binding sites. This is evidenced by the low selectivity of MIP towards fluconazole between multi-template compared to a single-template MIP.<sup>25,26</sup> This study aims to develop a MIP for fluconazole by analyzing interactions identified in prior research and incorporating established improvements for MIP synthesis that cannot be observable through laboratory experimentation. This is expected to enhance comprehension of designing a rational MIP design for fluconazole bioanalysis.

## 2 Methodology

### 2.1. Materials

**2.1.1. Chemicals.** Fluconazole was purchased from Tokyo Chemical Industry. Acrylic acid, itaconic acid, acrylamide, and 2-hydroxyethyl methacrylate were purchased from Sigma Aldrich, and dichloromethane and acetonitrile were purchased from Merck. All chemicals are analytical grade.

**2.1.2. Instruments.** Spectrophotometer UV/Vis Beckman Coulter DU720.

**2.1.3. Softwares.** MarvinSketch 24.3.0, Avogadro 1.2.0, Gaussian 09, Discovery Studio Visualizer v24.1.0.23298, Chemcraft 1.8, Yasara 21.12.19, Multiwfn 3.8, VMD 1.9.4a53, GIMP 2.10.32.

### 2.2. Analysis interaction of fluconazole with the monomer

The intermolecular interactions between fluconazole and the monomers were analyzed by performing an association constant ( $K_a$ ) experiment, which involved fluconazole and four functional monomers: acrylic acid (AA), itaconic acid (IA), acrylamide (ACR), and 2-hydroxyethyl methacrylate (HEMA). A continuous increment of functional monomers was added to the fluconazole solution in acetonitrile, initially at a concentration of 0.025 mM, until a 20-fold excess was reached. Absorbance measurements were taken for each increase in the functional monomer concentration at the maximum wavelength of fluconazole (260 nm). A graph was generated to illustrate the correlation between the change in absorbance ( $\Delta_{\text{absorbance}}$ ) and the concentration of the functional monomer. This graph was subsequently used to determine the association constant ( $K_a$ ) via the Benesi–Hildebrand equation. The  $K_a$  value obtained experimentally was compared to the  $K_a$  value derived from the mathematical calculations presented in prior research. To ensure reproducibility and reliability, the study was replicated three times. After the laboratory study, fluconazole–monomer complexes were analyzed using Discovery Studio



Table 1 List of monomers used in the simulation













Structure monomer	Name	Structure monomer	Name
			
Methacrylic acid	FM-1	2-Naphthylmethacrylate	FM-21
			
Itaconic acid	FM-2	9-Antracenylmethylmethacrylate	FM-22
			
Acrylic acid	FM-3	4-ethylstyrene	FM-23
			
p-vinylbenzoic acid	FM-4	trans-3-(3-pirydy)-acrylic acid	FM-24
			
2-(Trifluoromethyl)-acrylic acid	FM-5	Allylamine	FM-25
			
-Acrylamido-2-methyl-1-propanesulfonic acid	FM-6	N-(2-aminoethyl)methacrylamide	FM-26



Table 1 (Contd.)













Structure monomer	Name	Structure monomer	Name
	FM-7		FM-27
2-Acrylamido-1-ethanesulfonic acid		N-(t-butyl)acrilamide	
	FM-8		FM-28
4-vinylbenzeneboronic acid		N,N'-Diethyl-4-vinylbenzidine	
	FM-9		FM-29
Acrylamide		N-(3-aminopropyl) methacrylamide	
	FM-10		FM-30
Methacrylamide		N-(3,5-Bis(trifluoromethyl)phenyl)-N'-(4-vinylphenyl)urea	
	FM-11		FM-31
Methyl methacrylate		N,N-diethylaminomethylmethacrylate	
	FM-12		FM-32
2-Hydroxyethylmethacrylate		1-Vinylimidazole	



Table 1 (Contd.)
















Structure monomer	Name	Structure monomer	Name
	FM-13		FM-33
<chem>N-(2-hydroxyethyl)acrylamide</chem>		<chem>N,N,N-trimethylaminoethylmethacrylate</chem>	
	FM-14		FM-34
<chem>Styrene</chem>		<chem>4(5)-Vinylimidazol</chem>	
	FM-15		FM-35
<chem>4-Cyanostyrene</chem>		<chem>4-Vinylpyridine</chem>	
	FM-16		FM-36
<chem>Acrylonitrile</chem>		<chem>2-Vinylpyridin</chem>	
	FM-17		FM-37
<chem>N-vinyl-2-pyrrolidinone</chem>		<chem>N,N'-diethyl-4-styrylamidine</chem>	
	FM-18		FM-38
<chem>4-Vinylveratrole</chem>		<chem>N-vinylpyrrolidone</chem>	



Table 1 (Contd.)

Structure monomer	Name	Structure monomer	Name
	FM-19		FM-39
	FM-20		

Visualizer software to investigate the intermolecular interactions formed in the prepolymerization complex solution.<sup>27</sup>

$$\frac{1}{\Delta A} = \frac{1}{A\Delta HG} K_a[G] + \frac{1}{A\Delta HG} \quad (1)$$

$\Delta A$ : absorbance change,  $[G]$ : concentration of monomer (M),  $HG$ : template–monomer complex concentration (M), and  $K_a$ : association constant ( $M^{-1}$ ).

### 2.3. Computational investigations to enhance the performance of MIP fluconazole

The design for MIP fluconazole enhancement was carried out computationally by improving the theoretical level calculation, enlarging the number of monomers used in the interaction, and increasing the method used associated with interactions, which is expected to offer further understanding of establishing a rational MIP design for fluconazole bioanalysis. MarvinSketch was utilized for illustrating the structures of 39 functional monomers as shown in Table 1. Additionally, we applied a data-driven approach to group the monomers based on their acid–base properties. Specifically, monomers 1–8 were classified as acidic, monomers 9–24 as neutral, and monomers 25–39 as basic. This clustering strategy enabled a more systematic investigation of the interactions between fluconazole and the monomers, facilitating the identification of key characteristics that influence rational MIP design. The method employed molecular recognition as the host–guest interaction. Fluconazole serves as the host, whereas monomers act as guest molecules. Enhancements were implemented in the calculation methodology to achieve conditions that closely approximate

experimental results by transitioning from HF 3-21G to DFT B3LYP/6-311G++(d,p) level theory equipped with the DFT-D3 dispersion correction method. The 3D structure of fluconazole and monomers was built using Avogadro<sup>28</sup> followed by the optimization geometry of all initial structures using Gaussian.<sup>29</sup> Structural parameters are assessed to verify the appropriateness of the computational approaches.

**2.3.1. Complex formation and analysis.** The optimized molecular structures of fluconazole and the 39 monomers were utilized to construct template–monomer complexes. The initial coordinates of these complexes were obtained through molecular docking simulations using YASARA. Prior to the docking simulations, electrostatic potential (ESP) analysis was conducted to gain a deeper understanding of the molecular recognition processes between fluconazole and the monomers. The optimized structures of fluconazole and all 39 monomers from the geometry optimization study were converted to .pdb files. Molecular docking was performed using the blind docking method, wherein fluconazole was input into YASARA. The simulation cell was defined by selecting a cubic search space, with a grid box size set to  $40 \times 40 \times 40$  Å for all 39 simulations. The study was replicated to ensure the reliability of the protocol. During the molecular docking simulations, fluconazole, acting as the host, was kept rigid, while the monomers, acting as guests, were allowed flexibility. A 1 : 1 mole ratio between the host and guest was maintained throughout the simulations. Post-docking analysis was conducted to examine the complexes generated from the simulations. This analysis focused on evaluating the structures formed between fluconazole and the monomers, assessing the binding affinity, and analyzing the



intermolecular interactions between fluconazole and the monomers.

**2.3.2. Complexation energy and thermodynamic study.** The 39 complex conformations exhibiting the lowest binding affinity from docking simulations were selected for geometry optimization and frequency initial structure calculation. The three principal thermodynamic parameters analyzed were Gibbs free energy (G), entropy (S), and enthalpy (H). The study was performed within vacuum and solvated conditions using the solvent model density (SMD) approach. The solvation method was conducted in acetone, acetonitrile, chloroform, dichloromethane, and dimethyl sulfoxide, which have been used as solvents commonly used in MIP synthesis.

**2.3.3. Frontier molecular orbital (FMO) analysis.** The utilization of FMO analysis allowed for a comprehensive examination of complex stability based on the states of the Highest Occupied Molecular Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) to examine the optimal conditions for the fluconazole–monomer complex formation. Chemcraft was utilized to observe the structure parameters and visualize the three-dimensional structure of the 39 complexes in the vacuum and five solvated conditions.

**2.3.4. Quantum theory of atoms in molecules (QTAIM).** Various approaches were employed to assess the interaction in the complexes. The non-covalent interaction behavior between the template and the monomer in the optimal complex candidate was analyzed using various methods, such as QTAIM analysis, which is analyzed using the Multiwfn software package<sup>30</sup> and VMD.<sup>31</sup>

**2.3.5. Natural bond orbital (NBO).** To investigate the interactions between fluconazole as the template molecule and the optimized functional monomer for MIP synthesis that can't be observable through experimental study in the laboratory, the NBO investigation was carried out utilizing the NBO program.<sup>32</sup>

**2.3.6. Non-covalent interactions-reduce density gradient (NCI-RDG).** The investigation of NCI-RDG method was investigated using the GIMP program.<sup>33</sup> The sample input scripts for the optimization, thermodynamics, and NBO calculations were provided in the ESI: Computational settings and scripts.†

**2.3.7. Examination of multiple monomer interactions with the template.** The optimal monomer candidates identified in the previous study were subjected to further analysis through GFN-xTB simulations to investigate the influence of multiple monomers on fluconazole as the template molecule. The extended semi-empirical tight-binding model was employed to assess the interactions and behavior between fluconazole and the multiple monomer entities.

## 3 Results and discussion

### 3.1. Analysis interaction of complex

The choice of functional monomers is a critical factor influencing the selectivity and performance of molecularly imprinted polymers (MIPs). The functional groups of the monomers interact with the template molecule during the pre-polymerization stage, forming complexes that dictate the MIP's characteristics. These interactions significantly impact

the final properties of the MIP, including its binding capacity and selectivity for the target molecule. The stronger the interaction between the template and the monomer, the more pronounced the MIP's bonding capacity and selectivity.<sup>34</sup> In this study, the strength of the interaction between fluconazole, as the template molecule, and the selected monomers was assessed using the UV spectrophotometry method to determine the association constant ( $K_a$ ). The association constant is determined by evaluating the slope and intercept values through the Benesi–Hildebrand equation by plotting a graph of  $1/[\text{monomer}] [M^{-1}]$  vs.  $1/\Delta_{\text{absorbance}}$ .<sup>35</sup> The  $K_a$  value exhibits a broad spectrum; it is below  $25 M^{-1}$  for weak intermolecular interactions and exceeds  $100 M^{-1}$  for strong intermolecular interactions.<sup>36,37</sup> The results reveal that  $K_a$  values obtained with the complex formed between fluconazole and four monomers above  $100 M^{-1}$ , demonstrate a strong interaction between the template and the monomer.

The interaction of the complex generated during UV titration was examined using computational analysis. The complex that formed through molecular docking between fluconazole and each monomer was observed. The findings in Fig. 1 demonstrate that the intermolecular interactions within the complex formed by the template and monomer comprise hydrogen bonds, hydrophobic interactions, and halogen bonds. Intermolecular hydrogen bond interaction that formed between the template–monomer complex plays an essential role in enhancing the affinity of MIP, particularly for low molecular weight organic molecules in aprotic solvents<sup>38</sup> which is related to the UV titration study.

The computational method can be employed to assess hydrogen bond interactions between the template and monomer.<sup>39</sup> The  $K_a$  value acquired from the experiment was compared with the  $K_a$  value determined from the computational analysis utilized in prior research which included computational analysis utilizing the HF-321 G method, focusing on the assessment of geometry optimization and complex frequencies. A universally applicable thermodynamic relationship was established for the complexation constant in a dilute solution. The relationship is founded on a thermodynamic concept of the complexation equilibrium.<sup>40</sup> The free Gibbs energy of the complex, obtained from the frequency calculation of the optimal structure, can be utilized to determine the  $K$  value, which serves as a benchmark for the  $K_a$  value in laboratory experiments. The results in Fig. 2 indicate a difference between the  $K_a$  value derived from the UV titration experiment and the  $K$  value obtained from the computational calculation. While computational methods provide valuable theoretical insights into host–guest interactions, it is important to acknowledge that experimental data can be influenced by various factors such as sample preparation, solvent conditions, and instrumental limitations. These factors can introduce uncertainties that may not be captured by the computational models. Therefore, both sources of error, computational and experimental must be considered.

Among the four monomers investigated, acrylic acid was the only monomer that demonstrated a close correlation between the  $K_a$  and  $K$  values, indicating a strong interaction between







Fig. 1 Intermolecular interaction between FLU and monomer, green: hydrogen bond, cyan: halogen bond, pink: hydrophobic bond.



Monomer	$K_a$ ( $M^{-1}$ )	$\Delta G_{\text{complex}}$	$K$
AA	$1343.3 \pm 41.5$	-4.126	1066.600
IA	$976.6 \pm 57.4$	-3.138	200.966
ACR	$673.4 \pm 63.3$	1.486	0.081
HEMA	$785.1 \pm 83.4$	-1.860	23.175

Fig. 2 UV spectrum of FLU-monomer complex (top), association constant from experiment and computational study (bot).

fluconazole and this monomer. Acrylic acid was identified as the optimal monomer due to its higher yield compared to the other monomers, a finding consistent with previous study.<sup>26</sup> However, the discrepancy between the  $K_a$  and  $K$  values can be attributed to several factors inherent in the computational and experimental methodologies used. Firstly, the computational calculations were performed exclusively under vacuum conditions, which do not accurately reflect the actual experimental conditions. The UV titration experiments were conducted in acetonitrile, a solvent that can significantly influence the intermolecular interactions between the fluconazole (FLU)

template and the monomers. The solvent environment plays a critical role in modulating the binding affinity by affecting the solvation of the molecules and their interaction dynamics. Computational models that do not incorporate solvent effects may overlook these essential interactions, leading to discrepancies between the theoretical and experimental results. Furthermore, the computational approach used in this study relied on the HF 3-21G method, which, while widely utilized for investigating the binding energies of monomer–template complexes, has limitations. Specifically, the HF 3-21G method does not adequately account for dispersion interactions, which are crucial for accurately modeling non-covalent interactions such as hydrogen bonding, van der Waals forces, and hydrophobic interactions.<sup>41</sup> Dispersion interactions are particularly significant in weak binding systems like host–guest complexes, where these forces play a critical role in stabilizing the complex. The lack of proper treatment of dispersion forces can therefore result in an incomplete or inaccurate representation of the binding energy.

To address these limitations and improve the accuracy of our MIP design, it is essential to employ a more advanced level of theory that incorporates explicit solvation effects and better treatment of dispersion interactions. Methods such as Density Functional Theory (DFT) with dispersion corrections (*e.g.*, DFT-D3) would provide a more accurate description of the intermolecular interactions in solvated environments. Additionally, molecular dynamics simulations could be used to capture the flexibility of the system and the solvent's influence on the host–guest interactions, thus providing a more reliable and comprehensive prediction of the binding behavior. By refining our computational approach to include these advanced



methods, we aim to improve the design of the MIP, ensuring that the computational predictions are better aligned with experimental results and enhancing the overall performance of the MIP in bioanalytical applications.

### 3.2. Computational investigations to enhance performance of MIP fluconazole

With the limitations of the previous level of theory used, computational calculations can be developed with better methods and further analysis to be able to determine the type of intermolecular interactions that occur. The first improvement was carried out by improving the theoretical level calculation. The B3LYP/6-311G method was used because extensively employed to determine the optimal functional monomer for constructing highly selective MIP by computing reaction energy.<sup>42–44</sup> Numerous research studies on host–guest interactions have examined this level theory because of its effectiveness in investigating second-period atoms. In addition, the computational cost is acceptable while maintaining high accuracy.<sup>45,46</sup> The diffuse (++) and polarization (d,p) basis functions were added in order to enhance the computation method. Diffusion and polarization functions are essential in identifying non-covalent interactions that include hydrogen bonds, which play an essential part in the systematic design of MIPs.<sup>47</sup> Additionally, the DFT D3 correction was established to enhance the accuracy of our calculations by including intermolecular interactions in the calculation.<sup>48,49</sup> The structural parameter calculation was conducted by comparing the experimental crystal structure<sup>50</sup> and the optimized fluconazole structure from this method. No significant differences were observed when comparing the experimental results with the computational simulation of geometric parameters (Table 2).

Table 2 Structure parametrization of fluconazole

Geometric parameter	Experimental	Computational	Difference (%)
Distance F11–C5	1.356	1.351	0.33
Distance F10–C1	1.348	1.350	0.15
Distance O13–C12	1.408	1.421	0.92
Distance N27–N32	1.361	1.362	0.05
Distance N27–C18	1.459	1.451	0.56
Distance (N27–C28)	1.340	1.352	0.90
Distance N32–C29	1.321	1.323	0.15
Distance N33–C28	1.327	1.321	0.45
Distance N33–C29	1.350	1.362	0.89
Distance N21–N34	1.358	1.358	0.02
Distance C12–C4	1.528	1.534	0.39
Distance C4–C5	1.389	1.400	0.79
Angle N32–N27–C18	120.7	120.9	0.14
Angle C18–N27–C28	129.6	129.4	0.12
Angle N27–N32–C29	102.3	102.4	0.05
Angle C28–N33–C29	103.0	102.9	0.15
Angle C12–C4–C5	122.2	120.5	1.43
Angle F11–C5–C4	119.5	120.1	0.53
Angle N27–C28–N33	110.0	110.3	0.23
Angle N32–C29–N33	115.0	114.9	0.02

Thus, the theoretical levels can be utilized to examine the interactions between the host and guest that involve fluconazole as template molecules and functional monomers.

**3.2.1. Complex formation and analysis.** The further improvement of the computational design was the enlargement of monomers used in the interaction by using 39 monomers, including acidic, neutral, and basic monomers. The host–guest molecule inclusion complexes were acquired using molecular docking simulation of fluconazole and 39 monomers, which have been optimized using the DFT method. Before the molecular docking simulation, we perform ESP analysis of voriconazole, which is a fundamental factor driving host–guest interactions, which are essential for molecular recognition and binding. By analyzing the ESP of the host molecule, it becomes possible to predict, modulate, and optimize the interaction formed with the guest molecule. Positive ESP values are typically observed in regions near positive charges or electron-deficient areas, while negative ESP values correspond to regions that are rich in electron density or possess negative charges.<sup>51,52</sup> In the case of fluconazole as the host molecule, its electrostatic potential exhibits a complex distribution due to the presence of both positive and negative charges. Specifically, the nitrogen atoms within the triazole ring, which possess lone electron pairs, contribute to electron-deficient regions, resulting in positive electrostatic potential (positive ESP). Conversely, carbon atoms with varying electronegativities create regions of electron density, leading to negative ESP values. This dual distribution of electrostatic potential around fluconazole is critical for the host–guest interactions, as it creates a dynamic environment where both electron-deficient and electron-rich regions can facilitate molecular recognition and binding, further enhancing its ability to interact with functional monomers, as shown in Fig. 3.

The molecular docking simulations generated a total of 39 complex molecules. The binding energies of each complex were negative, as shown in Fig. 3. A negative binding affinity signifies that the complex is bonded spontaneously without requiring energy consumption. Lower binding energy values resulted in a more stable and stronger interaction between fluconazole and functional monomers.<sup>53</sup> The nature of intermolecular interactions within the complex was investigated. In the MIP synthesis, two main kinds of interactions are employed: covalent and non-covalent. The non-covalent method, which encompasses hydrogen bonds, dipole–dipole interactions, electrostatic interactions, and van der Waals bonds, is preferred due to its practical synthesis procedure, easy template removal, versatility in binding targets by monomers, and the potential to use a wide range of monomers.<sup>54</sup> A summary of the intermolecular interactions of all complexes is provided in Table S1 ESI.† The monomer that is capable of establishing hydrogen bonds with fluconazole was favored. Due to low-accuracy docking simulations, it is necessary to compare the obtained binding energy with the alternative method to determine the most stable conformation.<sup>55</sup> The coordinate input for further geometry optimization calculations was established from the conformation with the lowest binding energy obtained by molecular docking simulation.






Fig. 3 ESP of fluconazole (top) and binding affinity from molecular docking simulations (bot).

### 3.2.2. Complexation energy and thermodynamic study.

The interaction of fluconazole and the monomers impacts the binding affinity of MIP. The stronger interaction resulted in a more stable complex and higher imprinting efficiency of the resultant polymers, as shown by a lower complexation energy value. The calculation of complexation energy ( $\Delta E_{\text{complex}}$ ) was conducted in a vacuum and solvated conditions by using the subsequent equation:

$$\Delta E_{\text{complex}} = E_{\text{complex}} - (E_{\text{fluconazole}} + E_{\text{monomer}}) \quad (2)$$

Among several implicit solvation models, SMD model has gained popularity for computing condensed phase properties and has been employed in prior host-guest studies.<sup>56–58</sup>

Fig. 4 shows that all complexes had significantly negative energy values in their  $\Delta E_{\text{complex}}$  profiles, implying an energy-driven process. The system's stability increases with a decrease in the value of  $\Delta E_{\text{complex}}$ .<sup>59</sup> The  $\Delta E_{\text{complex}}$  value was found to be minimal under vacuum conditions, and the  $\Delta E_{\text{complex}}$  value changed under solvated conditions, indicating that the solvent influences the intermolecular interactions within the complex. Intermolecular interactions are exclusively observed between the host and guest molecules in a vacuum condition. Nevertheless, under solvated conditions, the possibility for interaction expands to include host, guest, and solvent molecules. The complex molecule demonstrates a remarkable interaction with

the solvent, therefore resulting in a modification of the intermolecular hydrogen bonds.<sup>60,61</sup> The basic properties of the solvent are crucial to guarantee the stability of the complexation process. The solvating capacity of the solvent has a considerable impact on the selectivity of complexation and the stability of the complexes. This can lead to significant changes in the binding characteristics of the template molecule.<sup>62</sup>

In addition to having a strong interaction with the template, the monomer must spontaneously bind to the template. Thermodynamic parameters are the most suitable for determining whether a process occurs spontaneously. The thermodynamic parameters were represented in terms of Gibbs free energy ( $\Delta G$ ), enthalpy ( $\Delta H$ ), and entropy ( $\Delta S$ ). The optimal compound from previous research was calculated for its thermodynamics in vacuum and dissolved conditions, both at a temperature of 298.15 K and a pressure of 1 atm. The utilization of the following calculation determined the parameters:

$$\Delta G_{\text{complex}} = G_{\text{complex}} - (G_{\text{fluconazole}} + G_{\text{monomer}}) \quad (3)$$

$$\Delta H_{\text{complex}} = H_{\text{complex}} - (H_{\text{fluconazole}} + H_{\text{monomer}}) \quad (4)$$

$$\Delta S_{\text{complex}} = S_{\text{complex}} - (S_{\text{fluconazole}} + S_{\text{monomer}}) \quad (5)$$

The complexation process will proceed spontaneously if the Gibbs free energy is negative. The result demonstrated that only






Fig. 4 Complexation energy (top) and free Gibbs energy (bot) in the vacuum and solvated conditions.

a limited number of monomers had a negative  $\Delta G_{\text{complex}}$ , suggesting that not all monomers possess the ability to bind spontaneously with the fluconazole as a template molecule. Compatibility between the template and functional monomer is essential for their interaction. The acid functional monomer exhibits a stronger interaction with the base template molecule, and conversely, the base template compound also shows a stronger interaction with the acid functional monomer.<sup>63</sup>

Table S2 ESI† provides a comprehensive overview of all complex thermodynamic parameters ( $\Delta H$ ,  $\Delta S$ , and  $\Delta G$ ). The results indicate that an exothermic process characterizes the formation of all complexes in both vacuum and solvents and is primarily influenced by changes in enthalpy. The molecular interaction between the monomers and the template is likely responsible for the negative value of this enthalpy.<sup>64</sup> A negative change in entropy ( $\Delta S < 0$ ) suggests that the formation of all complexes was not favored under both vacuum and solvated conditions. If a reaction is exothermic and the entropy is positive (indicating increased disorder), the change in free energy will always be negative, resulting in a spontaneous reaction.<sup>59</sup> The selection of the 39 monomers used in our study was based on those commonly employed in MIP synthesis. Fluconazole, being a weakly basic triazole antifungal compound, is theoretically expected to interact most strongly with basic monomers compared to neutral or acidic monomers. As a result, we

prioritized the study of acidic monomers (1–8), followed by neutral monomers (9–24), and finally, basic monomers (25–39). Based on binding energy docking, hydrogen bond formation in intermolecular interaction, complexation energy, and thermodynamic parameters, 2-acrylamido-1-ethanesulfonic acid (monomer 7) was the optimal monomer and was selected for further study.

**3.2.3. FMO analysis.** To comprehend the complex's stability under solvated conditions, additional research was undertaken employing FMO analysis derived from the quantum chemical parameters.<sup>61</sup> By examining the conditions of the lowest unoccupied molecular orbital (LUMO) and the highest occupied molecular orbital (HOMO), FMO analysis provides a comprehensive explanation for the complex stability. The HOMO and LUMO parameters, which were first defined using Koopman's theory and Parr functions within the framework of DFT theory, were used to construct most of the quantum descriptors.<sup>65–68</sup> FMO analysis was conducted on each complex under both vacuum and solvated conditions. However, the subsequent discussion concentrated mainly on complex 7 which formed from the fluconazole and 2-acrylamido-1-ethanesulfonic acid, the optimal complex according to the study. To comprehend the HOMO–LUMO process for FMO analysis in complex 7, it is necessary to examine the relevant orbital. HOMO is categorized as a nucleophile; meanwhile,



LUMO is an electrophile. Chemical reaction and resonance may both be explained by the overlap of an unfilled LUMO and a completely occupied HOMO. In FMO theory, the structure and reactivity of molecules are determined using these assumptions.<sup>69</sup>

The orbital distribution that defines the HOMO–LUMO transition is illustrated in Fig. 5. LUMO is mainly located in the host molecule; meanwhile, the HOMO is primarily located in the guest molecule suggesting fluconazole is more electrophilic than monomer 7. Complex 7's HOMO and LUMO orbitals were found to be localized from the guest to the host, as indicated by the observed result, which induced the charge transfer from monomer 7 to fluconazole.<sup>59</sup> Further explanation of complex 7 charge transfer was identified through natural population analysis (NPA). Both fluconazole and monomer 7 natural charge before interactions were zero (Table 3). When monomer 7 docked with fluconazole as the host, the overall natural charge changed. Fluconazole's total natural charge turns positive, whereas monomer 7 acquires a negative charge. The highest charge transfer was exhibited in a vacuum, with chloroform showing the second highest in solvated conditions. The complex 7 charge transfer was confirmed using structure parameterization, which involved comparing the structure of the complex in both vacuum and solvated conditions. An investigation was carried out between the intermolecular interaction of the host and guest molecule, specifically the bonding between atoms N33 in fluconazole and H51 in monomer 7. The bond length between N33–H51 in vacuum and solvated environment is detailed in Table 3. The most minimal shift existed in chloroform, which exhibited a correlation with the charge transfer investigation.

The FMO parameters were analyzed to further examine the complex 7 structure's stability. The parameters that were assessed included: energy gap ( $E_g$ ), ionization potential (IP), electron affinity (EA), hardness ( $\eta$ ), softness ( $S$ ), electrophilicity index ( $\omega$ ), stabilization energy (SE), chemical potential ( $\mu$ ), and electronegativity ( $X$ ). The HOMO–LUMO energy derivation was used to derive all the parameters.<sup>70</sup>

$$E_g = E_{\text{LUMO}} - E_{\text{HOMO}} \quad (6)$$

Table 3 Charge transfer of complex 7 (top) and structure parameterization of N33–H51 bond in complex 7 at different solvents (bot)

Conditions	Total NPA		N33–H51 bond	
	Fluconazole	Monomer 7	Bond length (Å)	Difference (%)
Vacuum	0.0837	−0.0837	1.630	—
Acetone	0.1197	−0.1197	1.516	6.96
Acetonitrile	0.1257	−0.1257	1.499	8.00
Chloroform	0.1108	−0.1108	1.542	5.38
Dichloromethane	0.1231	−0.1231	1.500	7.97
DMSO	0.1206	−0.1206	1.514	7.13

$$\text{IP} = -E_{\text{HOMO}} \quad (7)$$

$$\text{EA} = -E_{\text{LUMO}} \quad (8)$$

$$\eta = (E_{\text{LUMO}} - E_{\text{HOMO}})/2 \quad (9)$$

$$S = 1/2\eta \quad (10)$$

$$\omega = \mu^2/2\eta \quad (11)$$

$$\text{SE} = -\mu^2/2\eta \quad (12)$$

$$\mu = 1/2(E_{\text{HOMO}} + E_{\text{LUMO}}) \quad (13)$$

$$X = (\text{IP} + \text{EA})/2 \quad (14)$$

The energy gap between the HOMO and the LUMO can be utilized to figure out the molecule's kinetic stability. A smaller gap corresponds to lower chemical stability, higher molecular reactivity, and weakened orbital interactions between host and guest molecules since it takes smaller energy to move an electron from HOMO to LUMO conditions.<sup>71</sup> The quantum chemical properties of complex 7 are presented in Table 4, while all the FMO parameters for all 39 complexes are provided in Table S3 ESI.† Chloroform was determined to be the best solvent compared to the others for the formation of complexes between fluconazole as the host and monomer 7 as the guest molecule,




Fig. 5 HOMO (left) and LUMO (right) of complex 7.



Table 4 FMO analysis of complex 7 at different solvents

Conditions	$E_g$	IP	EA	$\eta$	$S$	$\omega$	SE	$\mu$	$X$
Vacuum	5.728	7.332	1.604	2.864	0.175	3.485	-3.485	-4.468	4.468
Acetone	5.814	7.074	1.260	2.907	0.172	2.987	-2.987	-4.167	4.167
Acetonitrile	5.794	7.064	1.265	2.897	0.173	2.996	-2.996	-4.167	4.167
Chloroform	5.876	7.141	1.269	2.938	0.170	3.006	-3.006	-4.203	4.203
Dichloromethane	5.814	7.070	1.256	2.907	0.172	2.981	-2.981	-4.163	4.163
DMSO	5.807	7.051	1.245	2.903	0.172	2.963	-2.963	-4.148	4.148

based on the computation of the FMO parameters. Chloroform is a widely utilized solvent in MIP synthesis. During polymerization, it works as a dispersion medium and pore-forming agent. Chloroform is a polar aprotic solvent that is regularly used in non-covalent imprinting techniques due to its outstanding ability to provide substantial imprinting performance. During polymerization, it acts as a dispersion medium and a pore-forming agent.<sup>72,73</sup> Chloroform as the optimum solvent corresponds with the prior charge transfer studies and structural parameterization. The interaction mechanisms in complex 7 will be examined in more detail.

**3.2.4. QTAIM analysis.** In order to further confirm the specific type of interaction revealed in the prior investigation, a QTAIM analysis was conducted. Through the measurement of electron density at the bond critical point (BCP), the interaction was examined. BCP indicates the electron density at the “saddle point” where covalent and non-covalent bonds are formed between the two atoms. These parameters give significant information regarding BCP's properties<sup>74</sup> which is computed using the below equation.

$$\nabla^2\rho = \lambda_1 + \lambda_2 + \lambda_3 \quad (15)$$

$$H_{\text{BCP}} = G_{\text{BCP}} + V_{\text{BCP}} \quad (16)$$

In accordance with the AIM theory, the properties of bonds, specifically hydrogen bonds is validated by: (a) hydrogen bonds are confirmed by the existence of BCP between the acceptor and the donor groups, (b) at the BCP point, the value of  $\rho(r)$  must be

minimal, falling within the interval of 0.0020 to 0.0400 a.u., (c) the value of the  $\nabla^2\rho(r)$  must be a positive number within the range of 0.0240 to 0.1390 a.u.<sup>75</sup> Furthermore, the interaction characteristics were determined based on the  $\nabla^2\rho$ , the  $H_{\text{BCP}}$  parameter, and were classified into three distinct categories according to Rozas *et al.*<sup>76,77</sup> (i) weak hydrogen bonds and primarily electrostatic interactions are indicated by both the positive values of  $\nabla^2\rho$  and  $H_{\text{BCP}}$ , (ii) the presence of strong hydrogen bonds with a covalent character is indicated by both negative  $\nabla^2\rho$  and  $H_{\text{BCP}}$  values, (iii) moderate hydrogen bonds with partial covalent characteristics are recognized when  $\nabla^2\rho$  is positive while  $H_{\text{BCP}}$  is negative. The interaction strength may also be classified using the parameter  $|V/G|$ . Weak interaction is defined as  $|V/G|$  value below 1, whereas moderate interaction is identified as an  $|V/G|$  ranging from 1 to 2. The strong interaction is present when the  $|V/G|$  value is more than 2.<sup>78</sup>

Table S4 ESI† reveals the topological properties of complex 7 in both vacuum and solvated states. Ten intermolecular BCPs exist between fluconazole and monomer 7. The hydrogen bonds in system 9, formed between the H51 atom from monomer 7 and the N33 atom from fluconazole, were determined to be moderate hydrogen bonds, characterized by a positive  $\nabla^2\rho$  (0.0983) and a negative  $H_{\text{BCP}}$  (-0.0176). Nine others intermolecular BCPs exhibited weak hydrogen bonds, as indicated by a negative value for  $\nabla^2\rho$  and  $H_{\text{BCP}}$ . Furthermore, the bond between H51 and N33 in system 9 exhibited a moderate interaction with a  $|V/G|$  value of 1.4171, whereas the other BCPs displayed a weak interaction with a  $|V/G|$  value below 1. The




Fig. 6 BCP complex 7 in vacuum (left) and chloroform (right).



presence of a reliable hydrogen bond between the hydrogen atom in monomer 7 and the nitrogen atom in fluconazole is responsible for a moderate interaction in system 9. Further QTAIM analysis will be conducted on the effect of solvated conditions utilizing system 9. The vacuum and all solvated conditions exhibited positive  $\nabla^2\rho$  and negative  $H_{\text{BCP}}$  values. Moderate covalent hydrogen bonds were consistently detected throughout all conditions, with the difference in the ratio of  $|V/G|$  between solvated and vacuum conditions. The enhancement of the  $|V/G|$  ratio in the solvated state indicated a stronger interaction. Chloroform outperformed other solvents with the highest  $|V/G|$  ratio (1.6461). Chloroform as a solvent in the complex formation will enhance the hydrogen bonds in complex 7. The BCP of complex 7 in vacuum and chloroform is illustrated in Fig. 6, while the full BCP of complex 7 is provided in Fig. S1 ESI.†

The QTAIM study shows that systems 2 (O39–H25) and 4 (C43–N34) only exhibit BCP in vacuum conditions. In contrast, the BCP of systems 5 (C44–N34) and 6 (H48–N33) is exclusively observable in solvated states. Under vacuum situations, intermolecular interactions exclusively exist between fluconazole as host and monomer 7 as guest molecules. However, an interaction between the molecules and the solvent is potentially possible under solvated conditions. Interactions of complex molecules with the solvent can strengthen or weaken intermolecular hydrogen bonds.

**3.2.5. NBO analysis.** The NBO refers to the bonding orbital that is determined based on the highest electron density.<sup>79</sup> NBO analysis was used to comprehensively study the natural orbitals that play a primary role in hydrogen bond interactions in host–guest interactions.<sup>80</sup> The bond strength is given by NBO analysis in terms of stabilizing energy ( $E^{(2)}$ ).

$$E^{(2)} = qi \frac{F(i,j)}{\epsilon_j - \epsilon_i} \quad (17)$$

A larger  $E^{(2)}$  value indicated stronger and more persistent donor–acceptor orbital connections that increased the interactions between host and guest molecules.<sup>81</sup> The population trends and distribution of interaction types are presented in Table S5 ESI.† This table summarizes and simplifies the data gathered, specifically focusing on the complex 7 intermolecular interactions under both vacuum and solvated conditions. Complex 7 exhibited ten intermolecular interactions according to its BCP. Compared to vacuum circumstances, the overall  $E^{(2)}$  value significantly rises in solvated conditions. The solvents influence intermolecular interactions between the host and guest molecule. Vacuum conditions restrict interactions with host–guest molecules, leading to a decreased stabilization energy compared to the solvated conditions. In contrast to other solvents, chloroform exhibited the greatest total  $E^{(2)}$  value, which aligns with prior studies. System 9 (H51–N33) provides the largest contribution to the total  $E^{(2)}$  value in complex 7, confirming that a moderate hydrogen bond was formed between fluconazole and monomer 7 in the QTAIM analysis. Based on the  $E^{(2)}$  value in system 9, the hydrogen bond between the lone pair (LP) as donors in the N33 atom and the LP\* orbital

as acceptors in the H51 atom was the most energetic and potential interaction in the formation of intermolecular hydrogen bonds in complex 7.

**3.2.6. NCI-RDG.** A comprehensive overview of molecular interactions was provided by the NCI-RDG. The primary areas of interest for NCI-RDG are the steric effect, strong–weak interaction distribution, and interaction topology.<sup>82</sup> The existence of intermolecular interactions in complex 7 was validated using NCI-RDG which described using this following equation:

$$\text{RDG}(r) = \frac{1}{2(3\pi^2)^{1/3}} \frac{|\nabla\rho(r)|}{\rho(r)^{4/3}} \quad (18)$$

In the scatter plot, strong or significant interactions are categorized as follows: (a) strong intermolecular interactions like halogen or hydrogen bonds; (b) intramolecular interactions like covalent interactions and intramolecular hydrogen bonds. The weak interactions encompass two types: (a) van der Waals forces resulting from the polarization of electron clouds and (b) hydrophobic interactions such as  $\pi$ -stacking. In contrast, steric effects are manifested in the cyclic structure as a result of ring or angle strains. Fig. 7 illustrates the scatter plot function of the NCI-RDG isosurface of complex 7 in vacuum and chloroform, which is determined by multiplying electron density by the sign of the second Hessian eigenvalue ( $\text{sign}(\lambda^2)\rho$ ), which varies between  $-0.05$  and  $0.05$  a.u. Full NCI-RDG figures of complex 7 are displayed in Fig. S2 and S3 ESI,† meanwhile NCI-RDG figures of all complexes were provided in Table S6 ESI.†

By examining the RDG isosurface of complex 7, we can observe that there is a noticeable decrease in the population of strong interaction in chloroform compared to vacuum conditions, especially for bonding between H51–N3. The RDG isosurface in chloroform is missing the blue area (shown by the orange circle in vacuum), which validates the effect of solvated conditions in host–guest interaction in complex 7. Scatter plots of complex 7 later supported this conclusion in the vacuum and chloroform conditions, which were the best solvents in the prior investigation. In contrast to chloroform, the vacuum condition demonstrated a decreased  $\text{sign}(\lambda^2)\rho$  value, which signifies the existence of a strong interaction (intermolecular hydrogen bond) within the complex denoted by the yellow circle.<sup>83</sup> The lack of this specific region in chloroform and other solvated conditions of complex 7 suggests that the solvent will affect the intramolecular hydrogen bonds between fluconazole as the host and monomer 7 as the guest in the complex. This finding is consistent with the results of QTAIM and NBO investigations.

**3.2.7. Examination of multiple monomer interactions with the template.** Following the discovery that fluconazole, as a host molecule, displayed the most favorable interaction with 2-acrylamido-1-ethanesulfonic acid as a guest molecule, leading to the formation of complex 7 in chloroform as the optimal solvent, an additional investigation was carried out to evaluate the influence of multiple monomers in the pre-polymerization complex. In MIP synthesis, it is essential to determine the optimal template-to-functional monomer ratio to facilitate the formation of the pre-polymerization complex and improve the imprinting effect. Increasing the concentration of complex






Fig. 7 RDG isosurface and 2D scatter plot of complex.

components in the pre-polymerization mixture enhances the formation of binding cavities within the imprinted polymer, thus improving its selectivity for the target molecules. It is also critical to align the functionality of the template with the functional monomer, such as pairing a hydrogen bond donor

with an acceptor.<sup>84</sup> ORCA with GFN-xTB was employed to examine the interaction between fluconazole and multiple molecules of 2-acrylamido-1-ethanesulfonic acid. This approach strikes a balance between computational speed and reasonable accuracy, making it particularly suitable for small to




Fig. 8 Optimization energy (left) and interaction energy (left) of multiple monomer.



medium-sized molecules. It is especially advantageous for preliminary docking studies or when more computationally demanding methods are not feasible.<sup>85</sup> This method is parameterized to provide reliable descriptions of geometries, vibrational frequencies, and, importantly, non-covalent interactions such as dispersion and hydrogen bonding that are critical for the studies. Fluconazole was docked with one to eight molecules of the monomer, corresponding to the maximum number of hydrogen bonds that fluconazole can form (one donor and seven acceptors). The GFN-xTB method generated two key outcomes: optimization energy ( $E_{\text{opt}}$ ), representing the total energy of the optimized complex, and interaction energy ( $E_{\text{inter}}$ ), which is defined as the energy difference between the final host-guest complex and the individual components.<sup>86</sup>

Fluconazole was docked with one to eight molecules of the monomer, based on the maximum number of hydrogen bonds fluconazole can potentially form, consisting of one hydrogen bond donor and up to seven hydrogen bond acceptors. As shown in Fig. 8, the optimization energy of the complex decreased with the increasing number of 2-acrylamido-1-ethanesulfonic acid molecules docked to fluconazole. Larger systems tend to exhibit more degrees of freedom, enabling a broader exploration of the potential energy landscape and typically resulting in lower energy values. The interaction energy analysis revealed that the lowest  $E_{\text{inter}}$  value occurred at a 1 : 6 ratio, which was determined to be the optimal ratio for forming the pre-polymerization complex between fluconazole and 2-acrylamido-1-ethanesulfonic acid. This ratio can be considered for future template-monomer stoichiometry in MIP synthesis.

## 4 Conclusions

This work enhances the computational method of MIP design for fluconazole bioanalysis based on prior studies. The analysis of fluconazole's interaction with the monomer revealed that fluconazole exhibits a robust interaction with AA, IA, ACR, and HEMA, characterized by a high  $K_a$  value. The  $K_a$  value obtained from the UV titration experiment was compared with the  $K$  value generated through computational calculations. Acrylic acid demonstrated a strong correlation between  $K_a$  and  $K$  values, establishing it as the optimum monomer, providing higher synthesis yield than the other monomers from the prior study, suggesting that computational analysis can assist in the design of MIP. The design of MIP fluconazole was enhanced through computational methods by refining theoretical calculations, increasing the number of interacting monomers, and improving the methodologies associated with these interactions, which is anticipated to provide deeper insights into the rational design of MIP for fluconazole bioanalysis.

The geometric parameters generated from the structural parameterization indicate that the DFT calculation using B3LYP/6-311G++(d,p) level theory and DFT-D3 dispersion was suitable for the investigation. The method evaluated the host-guest interactions of fluconazole and 39 monomers. The negative binding affinity observed in all complexes resulting from molecular docking indicates the favorable complex formation between the template and the monomer molecule. All

complexes had a significantly negative value for  $\Delta E_{\text{complex}}$ , with minimal value observed under vacuum conditions. The thermodynamic study revealed that only a few monomers can spontaneously bind with fluconazole, as a negative  $\Delta G_{\text{complex}}$  shown. The thermodynamic study revealed that only a few monomers can spontaneously bind with fluconazole, as a negative  $\Delta G_{\text{complex}}$  shows 2-acrylamido-1-ethanesulfonic acid (monomer 7) was chosen as an optimal monomer. The stability of complex formation in various solvents was observed through the FMO study, which indicated that chloroform was the optimal solvent for the formation of complexes between fluconazole and monomer 7, surpassing the other solvents.

The QTAIM study revealed the presence of ten intermolecular BCPs between fluconazole and monomer 7. The hydrogen bonds in system 9, generated from the H51 atom from monomer 7 and the N33 atom from fluconazole, were found to be the strongest bond as revealed in the NBO study by the largest  $E^{(2)}$  value. Hydrogen bonds, van der Waals forces, and hydrophobic interactions between guest and host molecules dominated the 2D scatter plots and RDG isosurface with chloroform as the optimal solvent. The interaction energy from multi-monomer interaction showed that a 1 : 6 ratio is the best ratio in forming a pre-polymerization complex between fluconazole and 2-acrylamido-1-ethanesulfonic acid. Based on the results obtained from this investigation and the confirmation and validation of the outstanding stability exhibited by complex 7, the computational study provides an enhancement of prior studies and gives insight for further laboratory investigations.

## Data availability

The data supporting this article have been included as part of the ESI.†

## Author contributions

Untung Gunawan: Data curation, investigation, methodology, visualization, writing – original draft. Slamet Ibrahim: Supervision, writing – review & editing. Atthar Luqman Ivansyah: Resources, software, supervision, writing – review & editing. Sophi Damayanti: Conceptualization, supervision, writing – review & editing.

## Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

## Acknowledgements

This work was supported by Center for Higher Education Fund, Ministry of Education, Culture, Research, and Technology of the Republic of Indonesia and Indonesia Endowment Fund for Education (LPDP) from the Ministry of Finance of the Republic of Indonesia.



## References

- 1 F. Bongomin, S. Gago, R. O. Oladele and D. W. Denning, *J. Fungi*, 2017, **3**, 57.
- 2 K. Kainz, M. A. Bauer, F. Madeo and D. Carmona-Gutierrez, *Microb. Cell*, 2020, **7**, 143–145.
- 3 L. Chen, E. H. J. Krekels, P. E. Verweij, J. B. Buil, C. A. J. Knibbe and R. J. M. Brüggemann, *Drugs*, 2020, **80**, 671–695.
- 4 C. Firacative, *Mem. Inst. Oswaldo Cruz*, 2020, **115**, 1–9.
- 5 J. T. Loh and K. P. Lam, *Adv. Drug Delivery Rev.*, 2023, **196**, 114775.
- 6 C. P. Eades and D. P. H. Armstrong-James, *Med. Mycol.*, 2019, **57**, S307–S317.
- 7 WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action, WHO, 2022, vol. 43.
- 8 S. P. B. Tamo, *Infect. Dis. Clin. Microbiol.*, 2020, **2**, 91–102.
- 9 P. G. Pappas, C. A. Kauffman, D. R. Andes, C. J. Clancy, K. A. Marr, L. Ostrosky-Zeichner, A. C. Reboli, M. G. Schuster, J. A. Vazquez, T. J. Walsh, T. E. Zaoutis and J. D. Sobel, *Clin. Infect. Dis.*, 2016, **62**, e1–e50.
- 10 S. Pathadka, V. K. C. Yan, C. F. Neoh, D. Al-Badriyeh, D. C. M. Kong, M. A. Slavin, B. J. Cowling, I. F. N. Hung, I. C. K. Wong and E. W. Chan, *Drugs*, 2022, **82**, 1193–1205.
- 11 N. Barantsevich and E. Barantsevich, *Antibiotics*, 2022, **11**, 718.
- 12 M. A. Acquavia, L. Foti, R. Pascale, A. Nicolò, V. Brancalone, T. R. I. Cataldi, G. Martelli, L. Scrano and G. Bianco, *Talanta*, 2021, **224**, 121862.
- 13 G. Wong, A. Brinkman, R. J. Benefield, M. Carlier, J. J. De Waele, N. El Helali, O. Frey, S. Harbarth, A. Huttner, B. McWhinney, B. Misset, F. Pea, J. Preisenberger, M. S. Roberts, T. A. Robertson, A. Roehr, F. B. Sime, F. S. Taccone, J. P. J. Ungerer, J. Lipman and J. A. Roberts, *J. Antimicrob. Chemother.*, 2014, **69**, 1416–1423.
- 14 L. Xia, J. Yang, R. Su, W. Zhou, Y. Zhang, Y. Zhong, S. Huang, Y. Chen and G. Li, *Anal. Chem.*, 2020, **92**, 34–48.
- 15 U. Gunawan, S. Ibrahim, A. L. Ivansyah and S. Damayanti, *Pharmacia*, 2023, **70**, 1265–1281.
- 16 J. J. Belbruno, *Chem. Rev.*, 2019, **119**, 94–119.
- 17 W. J. Cheong, S. H. Yang and F. Ali, *J. Sep. Sci.*, 2013, **36**, 609–628.
- 18 M. Arabi, A. Ostovan, A. R. Bagheri, X. Guo, L. Wang, J. Li, X. Wang, B. Li and L. Chen, *TrAC, Trends Anal. Chem.*, 2020, **128**, 115923.
- 19 M. Szultka, R. Krzeminski, M. Jackowski and B. Buszewski, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2013, **940**, 66–76.
- 20 Z. R. Zad, S. S. H. Davarani, A. Taheri and Y. Bide, *J. Mol. Liq.*, 2018, **253**, 233–240.
- 21 Z. Dai, J. Liu, S. Tang, Y. Wang, Y. Wang and R. Jin, *J. Mol. Model.*, 2015, **21**, 290.
- 22 S. Suryana, Mutakin, Y. Rosandi and A. N. Hasanah, *Molecules*, 2021, **26**, 1891.
- 23 Z. Liu, Z. Xu, H. Liu, D. Wang, Y. Yang, Y. Duan, L. Ma and T. Lin, *Polymers*, 2021, **13**, 1–18.
- 24 K. B. Lipkowitz and M. A. Peterson, *Chem. Rev.*, 1993, **93**, 2463–2486.
- 25 S. Manzoor, R. Buffon and A. V Rossi, *Talanta*, 2015, **134**, 1–7.
- 26 U. Gunawan, S. Ibrahim, A. L. Ivansyah and S. Damayanti, *React. Funct. Polym.*, 2024, **200**, 105915.
- 27 D. SYSTÈMES, *Dassault Syst MES*, 2016, preprint.
- 28 M. D. Hanwell, D. E. Curtis, D. C. Lonie, T. Vandermeersch, E. Zurek and G. R. Hutchison, *J. Cheminf.*, 2012, **4**, 17.
- 29 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, *Gaussian 09*, Gaussian, Inc., Wallingford, CT, 2016.
- 30 T. Lu and F. Chen, *J. Comput. Chem.*, 2012, **33**, 580–592.
- 31 W. Humphrey, A. Dalke and K. Schulten, *J. Mol. Graphics*, 1996, **14**(27–28), 33–38.
- 32 E. D. Glendening, C. R. Landis and F. Weinhold, *J. Comput. Chem.*, 2019, **40**, 2234–2241.
- 33 The GIMP Development Team, *GNU Image Manipulation Program (GIMP), Version 3.0.4. Community, Free Software (license GPLv3)*, 2025, <https://www.gimp.org>.
- 34 S. Li, S. Cao, M. J. Whitcombe and S. A. Piletsky, *Prog. Polym. Sci.*, 2014, **39**, 145–163.
- 35 P. Thordarson, *Chem. Soc. Rev.*, 2011, **40**, 1305–1323.
- 36 R. Wang and Z. Yu, *Acta Phys.-Chim. Sin.*, 2007, **23**, 1353–1359.
- 37 D. Huo, L. Yang, C. Hou, H. Fa, X. Luo, Y. Lu, X. Zheng, J. Yang and L. Yang, *Spectrochim. Acta, Part A*, 2009, **74**, 336–343.
- 38 E. Verheyen, J. P. Schillemans, M. van Wijk, M.-A. Demeniex, W. E. Hennink and C. F. van Nostrum, *Biomaterials*, 2011, **32**, 3008–3020.
- 39 A. N. Hasanah, N. Safitri, A. Zulfa, N. Neli and D. Rahayu, *Molecules*, 2021, **26**, 5612.
- 40 R. D. Groot, *J. Chem. Phys.*, 1992, **97**, 3537–3549.
- 41 E. R. Johnson, I. D. Mackie and G. A. DiLabio, *J. Phys. Org. Chem.*, 2009, **22**, 1127–1135.
- 42 J. Liu, Z. Zhang, L. Yang, Y. Fan and Y. Liu, *J. Mol. Graphics Modell.*, 2019, **88**, 228–236.
- 43 T. A. Sales and T. C. Ramalho, *Theor. Chem. Acc.*, 2020, **139**, 31.
- 44 U. Gunawan, S. Ibrahim, A. L. Ivansyah and S. Damayanti, *Pharmacia*, 2023, **70**, 1265–1281.



- 45 A. H. Mazurek and Ł. Szeleszczuk, *Molecules*, 2022, **27**, 3874.
- 46 N. Bensouilah, H. Fisli, H. Bensouilah, S. Zaater, M. Abdaoui and B. Boutemour-Kheddis, *J. Mol. Struct.*, 2017, **1146**, 179–190.
- 47 E. Papajak and D. G. Truhlar, *J. Chem. Theory Comput.*, 2010, **6**, 597–601.
- 48 D. Imane, N. Leila, M. Fatiha, G. Abdelkrim, C. Mouna, L. Ismahan, B. Abdelazize and H. Brahim, *J. Mol. Liq.*, 2020, **309**, 113233.
- 49 J. Hostaš and J. Řezáč, *J. Chem. Theory Comput.*, 2017, **13**, 3575–3585.
- 50 C. M. Orben and B. Dittrich, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2014, **70**, 580–583.
- 51 J. S. Murray and P. Politzer, *Wiley Interdiscip. Rev. Comput. Mol. Sci.*, 2011, **1**, 153–163.
- 52 C. H. Suresh and S. Anila, *Acc. Chem. Res.*, 2023, **56**, 1884–1895.
- 53 T. Pantsar and A. Poso, *Molecules*, 2018, **23**, 1.
- 54 T. Sajini and B. Mathew, *Talanta Open*, 2021, **4**, 100072.
- 55 G. Fitzgerald, J. DeJoannis and M. Meunier, in Woodhead Publishing Series in Electronic and Optical Materials, ed. V. K. Tewary and Y. B. T.-M. Zhang *Characterization, and Production of Nanomaterials*, Woodhead Publishing, 2015, pp. 3–53.
- 56 Y. Eken, N. M. S. Almeida, C. Wang and A. K. Wilson, *J. Comput.-Aided Mol. Des.*, 2021, **35**, 63–77.
- 57 S. A. Fahmy, F. Ponte, I. M. Fawzy, E. Sicilia and H. M. E.-S. Azzazy, *RSC Adv.*, 2021, **11**, 24673–24680.
- 58 S. Mirzaei, M. V Ivanov and Q. K. Timerghazin, *J. Phys. Chem. A*, 2019, **123**, 9498–9504.
- 59 Z. Jia, H. Pang, H. Li and X. Wang, *Theor. Chem. Acc.*, 2019, **138**, 1–11.
- 60 U. Gunawan, S. Ibrahim, A. Luqman Ivansyah and S. Damayanti, *J. Mol. Liq.*, 2023, **383**, 122130.
- 61 M. F. Akmal, D. Wahyuningrum and A. L. Ivansyah, *J. Mol. Liq.*, 2022, **366**, 120195.
- 62 M. Payehghadr and S. E. Hashemi, *J. Inclusion Phenom. Macrocyclic Chem.*, 2017, **89**, 253–271.
- 63 I. S. Ibarra, J. M. Miranda, I. Pérez-Silva, C. Jardinez and G. Islas, *Anal. Methods*, 2020, **12**, 2958–2977.
- 64 B. C. Deka and P. K. Bhattacharyya, *Comput. Theor. Chem.*, 2017, **1110**, 40–49.
- 65 R. G. Parr, L. v. Szentpály and S. Liu, *J. Am. Chem. Soc.*, 1999, **121**, 1922–1924.
- 66 R. G. Parr and P. K. Chattaraj, *J. Am. Chem. Soc.*, 1991, **113**, 1854–1855.
- 67 R. G. Parr and R. G. Pearson, *J. Am. Chem. Soc.*, 1983, **105**, 7512–7516.
- 68 R. G. Parr, *Horizons of Quantum Chemistry*, ed. K. Fukui and B. Pullman, Springer Netherlands, Dordrecht, 1980.
- 69 Y. Li and J. N. S. Evans, *J. Am. Chem. Soc.*, 1995, **117**, 7756–7759.
- 70 J. Yu, N. Q. Su and W. Yang, *JACS Au*, 2022, **2**, 1383–1394.
- 71 C. D. D. Sundari, A. L. Ivansyah, O. Floweri, I. M. Arcana and F. Iskandar, *New J. Chem.*, 2022, **46**, 3966–3977.
- 72 L. Chen, X. Wang, W. Lu, X. Wu and J. Li, *Chem. Soc. Rev.*, 2016, **45**, 2137–2211.
- 73 W. Dong, M. Yan, Z. Liu, G. Wu and Y. Li, *Sep. Purif. Technol.*, 2007, **53**, 183–188.
- 74 E. Espinosa, E. Molins and C. Lecomte, *Chem. Phys. Lett.*, 1998, **285**, 170–173.
- 75 U. Koch and P. L. A. Popelier, *J. Phys. Chem.*, 1995, **99**, 9747–9754.
- 76 I. Rozas, I. Alkorta and J. Elguero, *J. Am. Chem. Soc.*, 2000, **122**, 11154–11161.
- 77 I. Alkorta, I. Rozas and J. Elguero, *Int. J. Quantum Chem.*, 2001, **86**, 122–129.
- 78 A. Kazachenko, F. Akman, M. Medimagh, N. Issaoui, N. Vasilieva, Y. N. Malyar, I. G. Sudakova, A. Karacharov, A. Miroshnikova and O. M. Al-Dossary, *ACS Omega*, 2021, **6**, 22603–22615.
- 79 A. E. Reed, L. A. Curtiss and F. Weinhold, *Chem. Rev.*, 1988, **88**, 899–926.
- 80 S. Ghosh, P. Chopra and S. Wategaonkar, *Phys. Chem. Chem. Phys.*, 2020, **22**, 17482–17493.
- 81 M. P. M. Costa, L. M. Prates, L. Baptista, M. T. M. Cruz and I. L. M. Ferreira, *Carbohydr. Polym.*, 2018, **198**, 51–60.
- 82 E. R. Johnson, S. Keinan, P. Mori-Sánchez, J. Contreras-García, A. J. Cohen and W. Yang, *J. Am. Chem. Soc.*, 2010, **132**, 6498–6506.
- 83 M. Panneerselvam, M. D. Kumar, M. Jaccob and R. V. Solomon, *ChemistrySelect*, 2018, **3**, 1321–1334.
- 84 T. Sajini and B. Mathew, *Talanta Open*, 2021, **4**, 100072.
- 85 S. D. Jackman, T. Mozgacheva, S. Chen, B. O’Huiginn, L. Bailey, I. Birol and S. J. M. Jones, *Bioinformatics*, 2019, **35**, 4448–4450.
- 86 C. Bannwarth, S. Ehlert and S. Grimme, *J. Chem. Theory Comput.*, 2019, **15**, 1652–1671.

